Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres
- PMID: 34611896
- DOI: 10.1111/bjh.17863
Poly(ADP-ribose)polymerase inhibitors-associated myeloid neoplasms: a retrospective study from the French Network of Pharmacovigilance centres
References
-
- Morice P-M, Leary A, Dolladille C, Chrétien B, Poulain L, González-Martín A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8(2):e122-34.
-
- Moore KN. PARP inhibitor associated treatment related myeloid neoplasms: what was a “Rare” complication may be less so. Gynecol Oncol. 2021;161(3):639-41.
-
- Short NJ, Rytting ME, Cortes JE. Acute myeloid leukaemia. Lancet. 2018;392(10147):593-606.
-
- Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020. Available from: https://www.nejm.org.proxy.insermbiblio.inist.fr/ https://doi.org/10.1056/NEJMra1904794
-
- Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources